Tenet's hospital sell-offs funded an ambulatory M&A bet; Q1 2025 EBITDA rose 13.6%

Tenet Healthcare entered 2025 a smaller hospital company on purpose. In the first quarter of 2024 it closed the sale of three South Carolina hospitals to Novant Health and six California hospitals to UCI Health and Adventist Health. A year later the arithmetic shows: net operating revenues slipped from $5.4 billion to $5.2 billion year over year and net income fell from $2.2 billion to $406 million — declines Tenet attributed to the divestitures rather than to demand.

The redeployment is ambulatory surgery. On the April 29, 2025 earnings call, CEO Saum Sutaria said Tenet will stay bullish on acquisitions, planning to spend about $250 million a year on M&A moving forward, with a preference for facilities that can process high-acuity cases. In Q1 2025 alone it added six new centers, including a strategic partnership with orthopedic and urology surgery provider Choice Care Surgery Center in Midland, Texas; across the system Tenet has earmarked $700–800 million for capital expenditures this year.

The results beat expectations. First-quarter EBITDA grew 13.6% year over year, ahead of both Wall Street's and the company's own forecasts. In ambulatory services, net revenue per case rose 9.1% while case volumes fell 2.1% — CFO Sun Park's evidence that Tenet is capturing higher-acuity work. The hospital business pulled its weight too: same-hospital admissions rose 4.4%, revenue per adjusted admission 2.8%, and salary, wage and benefit spend improved 260 basis points as contract labor kept falling.

Management credits last year's capacity management, recruitment and retention initiatives for the hospital gains, and is deliberately not repricing strategy for Washington: of the major for-profit health systems reporting that quarter, Tenet spent the least earnings-call time on tariffs or Medicaid cuts. 'Our priorities right now are still, in this environment, to continue to build and grow the business, rather than any kind of retreat,' Sutaria told investors.

Q1 2025 EBITDA rose 13.6% year over year, beating Street and company forecasts; ambulatory net revenue per case rose 9.1% even as volumes slipped 2.1%.

The divestitures traded top line for focus: the $5.4B-to-$5.2B revenue decline is the visible price of shedding nine hospitals.

Ambulatory acuity mix beats volume: revenue per case up 9.1% on a 2.1% volume dip is the model working as designed.

Cost programs compound: a 260-basis-point improvement in salary, wages and benefits plus falling contract labor helped lift EBITDA 13.6%.

Capital discipline over caution: roughly $250M a year for ambulatory M&A continues regardless of tariff and Medicaid noise, with contingency planning held in reserve.

Selling lower-return hospitals funds years of focused tuck-in M&A; a scaled ambulatory platform out-earns beds through acuity mix, so keep deploying capital instead of retreating.

On the call Tenet reaffirmed rather than raised full-year 2025 revenue and EBITDA guidance — 'we're early in the year,' Sutaria said. Tariff and Medicaid questions were not dictating strategy; contingency planning would ramp only if significant Medicaid changes looked likely, similar to how the operator tackled COVID-19. The about-$250 million-a-year ambulatory acquisition pace and the $700–800 million capital budget stand for 2025.